Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

158 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.
Moore JP, Klasse PJ. Moore JP, et al. Among authors: klasse pj. J Virol. 2020 Jun 26:JVI.01083-20. doi: 10.1128/JVI.01083-20. Online ahead of print. J Virol. 2020. PMID: 32591466 Free article. Review.
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.
Herrera C, Klasse PJ, Michael E, Kake S, Barnes K, Kibler CW, Campbell-Gardener L, Si Z, Sodroski J, Moore JP, Beddows S. Herrera C, et al. Virology. 2005 Jul 20;338(1):154-72. doi: 10.1016/j.virol.2005.05.002. Virology. 2005. PMID: 15932765
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
Herrera C, Klasse PJ, Kibler CW, Michael E, Moore JP, Beddows S. Herrera C, et al. Virology. 2006 Jul 20;351(1):121-32. doi: 10.1016/j.virol.2006.03.003. Epub 2006 Apr 17. Virology. 2006. PMID: 16616288
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
Dey AK, David KB, Klasse PJ, Moore JP. Dey AK, et al. Virology. 2007 Mar 30;360(1):199-208. doi: 10.1016/j.virol.2006.09.046. Epub 2006 Nov 7. Virology. 2007. PMID: 17092531 Free PMC article.
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP. Beddows S, et al. Virology. 2007 Apr 10;360(2):329-40. doi: 10.1016/j.virol.2006.10.032. Epub 2006 Nov 28. Virology. 2007. PMID: 17126869
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, Moore JP. Ketas TJ, et al. Virology. 2007 Aug 1;364(2):281-90. doi: 10.1016/j.virol.2007.02.022. Epub 2007 Apr 10. Virology. 2007. PMID: 17428518 Free PMC article.
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.
Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. Dey AK, et al. Virology. 2008 Mar 1;372(1):187-200. doi: 10.1016/j.virol.2007.10.018. Epub 2007 Nov 26. Virology. 2008. PMID: 18031785 Free PMC article.
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. Pugach P, et al. Virology. 2009 May 10;387(2):296-302. doi: 10.1016/j.virol.2009.02.044. Epub 2009 Mar 20. Virology. 2009. PMID: 19303620 Free PMC article.
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP. Banerjee K, et al. Virology. 2009 Jun 20;389(1-2):108-21. doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2. Virology. 2009. PMID: 19410272 Free PMC article.
158 results
Jump to page